• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

Total number of Public Inquiries by month (includes phone, email, and letter inquiries)

Dictionary: The Division of Drug Information within CDER is responsible for answering the public's questions about the regulatory mission of FDA. Questions arrive in the form of emails or postal mail. The public also calls the agency with many questions. This measure tracks the number of public inquiries CDER receives each month. It is CDER's goal to always respond to all public inquiries.


These measures have been retired as CDER has created new measures for FY13 which align to their four functional areas of 1) Regulatory Review and Drug Safety, 2) Drug Quality and Compliance, 3) Transparency and Public Outreach, and 4) Regulatory Science Research.

Fiscal Year - 2010

Skip graphic and jump to text data

TimeTargetNumber
Oct 2009N/A8,351
Nov 2009N/A6,711
Dec 2009N/A7,219
Jan 2010N/A8,574
Feb 2010N/A6,889
Mar 2010N/A9,162
Apr 2010N/A6,958
May 2010N/A7,171
Jun 2010N/A8,179
Jul 2010N/A7,441
Aug 2010N/A6,961
Sep 2010N/A5,966

Number of phone inquires received in the month

Dictionary: The Division of Drug Information within CDER is responsible for answering the public's questions about the regulatory mission of FDA. Questions arrive in the form of emails or postal mail. The public also calls the agency with many questions. This measure tracks the number of public inquiries CDER receives each month. It is CDER's goal to always respond to all public inquiries.

Fiscal Year - 2010

Skip graphic and jump to text data

TimeTargetNumber
Oct 2009N/A6,343
Nov 2009N/A5,008
Dec 2009N/A5,630
Jan 2010N/A6,734
Feb 2010N/A5,426
Mar 2010N/A7,217
Apr 2010N/A5,400
May 2010N/A5,516
Jun 2010N/A6,294
Jul 2010N/A5,727
Aug 2010N/A4,896
Sep 2010N/A4,235

Percent of phone calls with first contact resolution (i.e., phone call answered by FDA staff and response given; this statistic does not include phone calls received during non-business hours)

Fiscal Year - 2010
Skip graphic and jump to text data.

TimeTargetPercent
Oct 2009N/A65
Nov 2009N/A68
Dec 2009N/A71
Jan 2010N/A69
Feb 2010N/A73
Mar 2010N/A69
Apr 2010N/A68
May 2010N/A69
Jun 2010N/A63
Jul 2010N/A70
Aug 2010N/A65
Sep 2010N/A75

Number of email inquires received in the month

Dictionary: The Division of Drug Information within CDER is responsible for answering the public's questions about the regulatory mission of FDA. Questions arrive in the form of emails or postal mail. The public also calls the agency with many questions. This measure tracks the number of public inquiries CDER receives each month. It is CDER's goal to always respond to all public inquiries.

Fiscal Year - 2010

Skip graphic and jump to text data

TimeTargetNumber
Oct 2009N/A1,932
Nov 2009N/A1,620
Dec 2009N/A1,492
Jan 2010N/A1,783
Feb 2010N/A1,406
Mar 2010N/A1,732
Apr 2010N/A1,465
May 2010N/A1,567
Jun 2010N/A1,754
Jul 2010N/A1,592
Aug 2010N/A1,983
Sep 2010N/A1,634

Percent of emails responded to in 48 hours in the month

Fiscal Year - 2010
Skip graphic and jump to text data.

TimeTargetPercent
Oct 2009N/A100
Nov 2009N/A100
Dec 2009N/A100
Jan 2010N/A100
Feb 2010N/A100
Mar 2010N/A100
Apr 2010N/A100
May 2010N/A100
Jun 2010N/A100
Jul 2010N/A100
Aug 2010N/A100
Sep 2010N/A100

Number of letter correspondence received by CDER's Office of Communication in the month (30 day due date from time of receipt for a response by CDER's Office of Communications

Dictionary: The Division of Drug Information within CDER is responsible for answering the public's questions about the regulatory mission of FDA. Questions arrive in the form of emails or postal mail. The public also calls the agency with many questions. This measure tracks the number of public inquiries CDER receives each month. It is CDER's goal to always respond to all public inquiries.

Fiscal Year - 2010

Skip graphic and jump to text data

TimeTargetNumber
Oct 2009N/A76
Nov 2009N/A83
Dec 2009N/A97
Jan 2010N/A57
Feb 2010N/A57
Mar 2010N/A213
Apr 2010N/A93
May 2010N/A88
Jun 2010N/A131
Jul 2010N/A122
Aug 2010N/A82
Sep 2010N/A97

Glossary

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.